Lerkanidipin - blokator kal'tsievykh kanalov III pokoleniya


Cite item

Full Text

Abstract

About the authors

A A Kirichenko

References

  1. Garfield FB, Caro JJ. Compliance and hypertension. Curr Hypertens Rep 1999; 1: 502-6.
  2. Hill MN, Bone LR, Kim MT et al. Barriers to hypertension care and control in young urban black men. Am J Hypertens 1999; 12: 951-8.
  3. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43-9.
  4. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med 1997; 19: 239-63.
  5. Dusing R, Weisscr B, Mcngden T et al. Changes in antihypertensive therapy - the role of adverse effects and compliance. Stood Press 1998; 7: 313-5.
  6. Aranda P, Tamargo J, Aranda FJ et al. Use and adverse reactions of antihypertensive drugs in Spain. Blood Pros 1997 (Suppl. 1): 11-6.
  7. Caro JJ, Salas M, Speckman JL et al. Persistence with treatment for hypertension in actual practice. SMAJ 1999; 160: 31-7.
  8. Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2000; 2: 515-24.
  9. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Int Med 1996; 156: 1969-78.
  10. Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M. (ed). Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia. Hanley & Belfus 1998: 155-76.
  11. Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Drugs 1999; 58: 579-87.
  12. Corry DB, Tuck ML. Insulin and glucoregulatory hormones: implications for antihypertensive therapy. In: Epstein M. (ed). Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley &Belfus 1998: 215-42.
  13. Goldberg RB, Florez H. Effects of calcium antagonists on lipids. In: Epstein M. (ed). Calcium Antagonists™ Clinical Medicine. 2nd ed. Philadelphia: Hanley&Belfus 1998: 359-68.
  14. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
  15. Specchia G, Saccaggi SP, Ghezzi C. Cardiovascular safety of lercanidipine in patients with angina pectoris: are view of six randomized clinical trials. CURR Ther Res 2001; 62. 3-15.
  16. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipin AL: Short Plasma Half-Life, Long Duration of Action. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S19-S24.
  17. Ahernethy DR, Schwartz JB. Calcium-antagonistdrugs. N Engl J Med 1999; 341: 1447-57.
  18. Gasser R, Koppel H, Klein W. Lercanidipine, anew third generation Ca-antagonist in the treatment of hypertension. J Clin Basic Cardiol 1999; 2: 169-74.
  19. Leonardi A, Poggesi E, Tiiddei C et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S10-S18.
  20. Ninci MA, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S40-4.
  21. Angelico P, Guarneri L, Leonardi A et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51: 709-14.
  22. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95-100.
  23. Policicchio D, Magliocca R, Malliani A. Efficacy and to lerability of lercanidipine in patients with mild to moderate essential hypertension: acomparative study with slow-releas enifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31-5.
  24. Romito R, Pansini MI, Perticone F et al. Comparative effect of oflercanidipinelercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): 249-53.
  25. Pedrinelli R, Dell'Omo G, Nuti M et al. Heterogenous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003; 21: 1969-73.
  26. Cavallini A, Terzi G. Effect so fanti hypertensiv et herapy with lercanidipine and verapamil on cardia celectrical activity in patients with hypertension: arandomized, double-blindpilotstudy. Curr Ther Res 2000; 61 (7): 477-87.
  27. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): 236-53.
  28. Fogari R, Malamani GD, Zoppi A et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel group study. Curr Ther Res Clin Exp 2000; 61: 850-62.
  29. Barbagallo M, BarbagalloSangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375-9.
  30. Kizer IR, Kimmel SE. Epidemiologic review of calcium channel blocker drugs. Arch Intern Med 2001; 161: 1145-58.
  31. Joint National Committeeon Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
  32. Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipinevs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.
  33. S'anchez A, Sayans R, Alvarez JL et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract 12]. Fourth European Meeting on Calcium Antagonists. Amsterdam, 1999.
  34. Parving RH. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens 1990; 8: 5187-91.
  35. Peterson JE, Adler S, Burkart LM et al. Blood pressure control, proteinuria and the progression of renal disease: the odification of diet in renal disease study. Ann Intern Med 1995; 123: 754-62.
  36. Toto RD, Mitchell NC, Smith RO. «Strict» blood pressure control and progression of renal disease in hypertensive ephrosclerosis. Kidney Int 1995; 48: 851-9.
  37. Gansevoort RT, Sluiter WJ, Hemrnelder MH et al. Antiproteinuric effect of blood pressure lowering agents: a metaanalysisof comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74.
  38. Mald DD, Ma IZ, Louis TA, Kasiske BL. Long-term effects ofantihypertensive agents on proteinuria and renal function. Arch Intern Meet 1995; 155: 1073-80.
  39. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different anti-hypertensive drugs in human diabetic nephropathy:an updated metaanalysis. Nephrol Dial Transplant 1995; 10 (Suppl. 9): 39-45.
  40. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-72.
  41. Lewis E, Huncksicker LG, Clarke WR et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
  42. Parving III-I, Lehnert I-I, Brochner-Mortenscn I et al. For the study group Irbesartun in patients with type 2 diabetes and microalbumlnuria. N Engl J Med 2001; 345: 870-8.
  43. Agodoa LY, Appel L, Bakris GL et al. Effect of ramiprilvs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-28.
  44. Epstein M. Calcium antagonists and renal protection: emerging perspectives. J Hypertens 1998; 18 (Suppl. 4): S17-25.
  45. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-9.
  46. Bakris GL, Weir MR, DeQuattro V et al. The effects of an ACE inhibitor and a calcium antagonists on the progression of renal disease: the nephross study. Nephrol Dial Transplant 2001; J6: 2158-66.
  47. Robles NR, Ocon J, Gomez CF et al. Лерканидипин у пациентов с хронической почечной недостаточностью: исследование ZAFRA. Кардиоваск. тер. и профилакт. 2010; 9 (4) 81-7.
  48. Soma MR, Natali M, Donetti E et al. Effect of lercanidipine its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1998; 125: 1471-6.
  49. Lozano JV, Sanchis C, Llisterri JL. Efficacy of lercanidipine in poorly controlled hypertensive patients who follow a home blood pressure measurement training program [abstract R190]. J Hypertens 2002; 20 (Suppl. 4): S376.
  50. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95-100.
  51. Schwinger RHG, Schmidt-Mertens A. The new lipophilliccal ciumchannel blocker lercanidipine combines hig hanti hypertensive efficacy with low side effects [abstract P1-7]. Dtsch Med Wochenschr 2002; 127 (Suppl. 1): S13.
  52. Romito R, Pansini MI, Perticone F et al. Comparative effect of oflercanidipinelercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J ClinHypertens 2003; 5 (4): 249-53.
  53. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparisontoand in combination with at enolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26-30.
  54. Barbagallo M, Sangiorgi G. Efficacy and to lerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375-9.
  55. Acanfora D, Gheorgiade M, Rotiroti D et al. Acute dose-response, double-blind, placebo-controlled pilot study of Iercanidipine in patients with angina pectoris. Curr Ther Res 2000; 61: 255-65.
  56. Leonetti G, Magnani B, Pessina AC et al. Tolerability of longterm treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15 (11): 932-40.
  57. Borghi C, Prandin MG, Dormi A et al. Improved to lerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challen getrial. Blood Press 2003; 12 (Suppl. 1): 1-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 83918 от 12.09.2022 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 83917 от 12.09.2022 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies